Alzheimer Disease Clinical Trial
— VALIDOfficial title:
Volunteers Adding Life in Dementia (VALID)
Verified date | April 2017 |
Source | Queen's University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objectives of our project are to: 1.) Develop a training program and manual for volunteers to implement evidence-based, non-pharmacological interventions for neuropsychiatric symptoms (NPS) of dementia in long-term care (LTC) settings; 2.) Recruit and train volunteers using the VALID program and pilot test the volunteer-led program with 20 individuals with Alzheimer's disease and NPS in a LTC facility in Kingston; and, 3.) Evaluate the effects of the VALID program on the symptoms of NPS, patient quality of life, volunteer's experience, and LTC staff stress.
Status | Completed |
Enrollment | 75 |
Est. completion date | March 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - diagnosis of Alzheimer's disease or related forms of dementia - significant symptoms of agitation as measured by a Cohen-Mansfield Agitation Inventory (CMAI) total score of >39 - in nursing home for at least 30 days - presence of a caregiver or substitute decision maker willing to consent to treatment - no changes in psychotropic medications in the 2 weeks preceding enrolment in study Exclusion Criteria: - depressive symptoms presenting risk - physically aggressive behavior posing safety risk to others - uncontrolled pain - currently receiving palliative care - medically unstable with life expectancy of < 6 months - currently awaiting transfer to another LTC facility or hospital. |
Country | Name | City | State |
---|---|---|---|
Canada | Extendicare Kingston | Kingston | Ontario |
Lead Sponsor | Collaborator |
---|---|
Queen's University |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Cohen-Mansfield Agitation Inventory (CMAI) score | Baseline and 12 weeks | ||
Secondary | Clinically significant reduction in agitation | 30% reduction in CMAI score | Baseline and 12 weeks | |
Secondary | Remission of neuropsychiatric symptoms | CMAI score <40 | Baseline and 12 weeks | |
Secondary | Change in Neuropsychiatric Inventory (NPI) score | Baseline and 12 weeks | ||
Secondary | Change in depression symptoms (Cornell Depression in Dementia Rating Scale) | Baseline and 12 weeks | ||
Secondary | Dementia Quality of Life (DemQoL) Scale | Baseline and 12 weeks | ||
Secondary | Clinical Global Impression of Change (CGI-C) | Baseline and 12 weeks | ||
Secondary | Use and dose of required medication | Baseline and 12 weeks | ||
Secondary | Short form health survey | Volunteer quality of life | Baseline and 12 weeks | |
Secondary | Change in Modified Nursing Care Assessment Scale score | Assessing nursing stress. | Baseline and 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |